Research on the Role of SLC1A5 in the Development of Esophageal Cancer

Esophageal Cancer Clinical Trial

Official title:

Research on the Role of the Amino Acid Transporter SLC1A5 in the Development of Esophageal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02633436
• Other study ID #: PJK201518
• Status: Recruiting
• Phase: N/A
• First received: December 6, 2015
• Last updated: August 11, 2016
• Start date: December 2015
• Est. completion date: August 2018

Study information

• Verified date: August 2016
• Source: Fourth Affiliated Hospital of Guangxi Medical University
• Contact: Shengming Dai, Dr.
• Phone: +86 13978026884
• Email: daishm[@]sina.com
• Is FDA regulated: No
• Health authority: China: Health and Family Planning Commission of Guangxi Zhuang Autonomous Region
• Study type: Observational

Clinical Trial Summary

To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.

Description:

This will be an observational study. The investigators will aim to enroll 100 male and female adult patients (aged 18 years and over) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for esophageal cancer.

The investigators will be using a standardized data collection form. This is an observational study in which standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent. An attempt will be made to see if there is a correlation between the expression of SLC1A5 with esophageal cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: August 2018
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with histologically proven esophageal cancer;

2. Age =18 years;

3. All patients must sign consent forms voluntarily;

Exclusion Criteria:

1. Inability to obtain histologic proof of malignancy.

2. Age <18 years;

Study Design

Observational Model: Case-Only

Related Conditions & MeSH terms

• Amino Acid Metabolism, Inborn Errors
• Amino Acid Transport Disorder
• Esophageal Cancer
• Esophageal Neoplasms

Intervention

Other:
• SLC1A5 expression
To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.

Locations

Country	Name	City	State
China	Liuzhou Maternity and Child Healthcare Hospital	Liuzhou	Guangxi
China	The Fourth Affiliated Hospital of Guangxi Medical University	Liuzhou	Guangxi

Sponsors (2)

Lead Sponsor	Collaborator
Fourth Affiliated Hospital of Guangxi Medical University	Liuzhou Maternity and Child Healthcare Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	optical density (ODs) of each slice by immunohistochemistry assay	For immunohistochemistry assay: Briefly, the samples will be cut into slices, which will be stained with standard steps. Finally, three high power fields will be randomly selected from each slice and the average optical density (OD) will be measured in each field.	within one year (plus or minus 1 month) after surgery	Yes
Secondary	SLC1A5 expression detected by WesternBlot	Western blot assay will be done by comparing the intensity of bands. To start with, xray film will be scanned on a flat-bed scanner. Then the grayscale image will be analyzed with software. Finally the Gray Value of each band will be obtained for analysis.	within one year (plus or minus 1 month) after surgery	Yes